Overview

A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture

Status:
Recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

A multicenter, randomized, double-blind, placebo-controlled phase III clinical study will be conducted to evaluate the efficacy and safety of LY06006 in the treatment of postmenopausal women with osteoporosis at high risk for fracture, as well as an exploratory population pharmacokinetic analysis of LY06006.

Phase:

Phase 3

Details

Lead Sponsor:

Luye Pharma Group Ltd.

Collaborator:

Shang Dong Boan Biotechnology Co., Ltd (Co-sponsor)